Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control
Asuragen, Inc. has developed an Armored RNA Quant® SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic. Asuragen’s proprietary Armored RNA Quant technology has been included in FDA-approved assays for over 20 years and is the gold standard for reliable, traceable standards for use with molecular assays developed for virus quantitation.
The widespread and aggressive nature of COVID-19 has prompted a global effort to facilitate rapid and accurate testing for SARS-CoV-2. The Armored RNA Quant SARS-CoV-2 Control targets the SARS-CoV-2 viral nucleocapsid (N) region and, along with the company’s new RNAse P construct, aligns with the CDC and WHO-recommended Diagnostic Panel (CDC-006-00019) to provide a safe, stable, and reliable way to test for the novel coronavirus. Armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.
“As the global healthcare community works to contain the spread of this disease, expediting the development of rapid and accurate testing is of paramount importance for laboratories everywhere,” said Matthew McManus, MD, PhD, president and CEO of Asuragen. “With our new SARS-CoV-2 Control, we are committed to supporting these efforts as we collectively work to identify – and ultimately care for – those affected with COVID-19.”
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RELIEF-THERAPEUTICS7.4.2020 07:32:12 CEST | Press release
Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress
NY-INTERNATIONAL-WELL6.4.2020 23:05:05 CEST | Press release
IWBI Announces New Co-chairs and More than 225 Members of the Task Force on COVID-19 and Other Respiratory Infections: Prevention and Preparedness, Resilience and Recovery
CQN-TAKEDA-PHARMA6.4.2020 20:00:10 CEST | Press release
CORRECTING and REPLACING Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
COGNITE6.4.2020 18:02:08 CEST | Press release
Cognite Awarded Google Cloud Technology Partner of the Year 2019 for Manufacturing
VERIMATRIX6.4.2020 17:47:08 CEST | Press release
Verimatrix Announces Server-side Watermarking Integration with Akamai Intelligent Edge Platform
ALPEGA-GROUP6.4.2020 16:02:09 CEST | Press release
Alpega TMS Brings Together the Expertise of inet and Transwide
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom